BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1181 related articles for article (PubMed ID: 33197924)

  • 1. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
    Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
    J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
    Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
    Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
    J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2
    Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL
    J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
    J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Zeng J; Mao WM; Chen QX; Luo TB; Wu YL; Zhou Q; Yang XN; Yan HH; Zhong WZ; Wang Q; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT
    Lung Cancer; 2020 Dec; 150():164-171. PubMed ID: 33186858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
    Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
    Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.